PA007614.m2a:In Vivo Grade Recombinant Anti-human CD62E (E-selectin) Monoclonal Antibody (Clone: CL2), Mouse IgG2a Kappa
Recombinant Mouse IgG2a Monoclonal Antibody.
Clone: CL2.
Isotype: Mouse IgG2a Kappa.
Source:The anti-human CD62E (E-selectin) monoclonal antibody (clone: CL2) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: CL2) specifically binds to human CD62E (E-selectin).
Applications:ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CD62E (E-selectin) protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The in vivo grade recombinant anti-human CD62E (E-selectin) monoclonal antibody of clone CL2 is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
References of anti-human CD62E (E-selectin) antibody (Clone: CL2):
Nasal administration of anti-CD3 monoclonal antibody ameliorates disease in a mouse model of Alzheimer’s disease
Kuhn, C., et al. Proc Natl Acad Sci U S A. 2023 Sep 5;120(36):e2309221120. doi: 10.1073/pnas.2309221120. PMID: 37669420
Nasal administration of the anti-CD3 monoclonal antibody (clone CL2) induced regulatory T cells (Tregs), ameliorating disease in mouse models of Alzheimer’s disease, multiple sclerosis, diabetes, lupus, and arthritis. In a progressive EAE model, it reduced microglia and astrocyte inflammation in the CNS, supporting its potential to address Treg dysfunction in Alzheimer’s disease.
Tags: anti-human CD62E (E-selectin) CL2; anti-human CD62E (E-selectin) (CL2) in vivo antibody
A CD3 humanized mouse model unmasked unique features of T-cell responses to bispecific antibody treatment
Wang, L., et al. Blood Adv. 2024 Jan 23;8(2):470-481. doi: 10.1182/bloodadvances.2023005827. PMID: 38231088
Flow cytometric analysis using the anti-CD3ε antibody (clone CL2) assessed T cell activation in B-hCD3E and B-hCD3EDG mice treated with anti-CD3/CD19 and anti-CD3/BCMA bispecific antibodies. In MC38-based tumor models, blinatumomab and anti-CD3/BCMA antibodies dose-dependently inhibited tumor growth, highlighting the model’s utility for evaluating T-cell engager efficacy.
Tags: anti-human CD62E (E-selectin) CL2 antibody; anti-human CD62E (E-selectin) antibody (clone CL2)
Immunological analysis of the murine anti-CD3-induced cytokine release syndrome model and therapeutic efficacy of anti-cytokine antibodies
Schmied, L., et al. Immun Inflamm Dis. 2021 Jun;9(2):265-282. doi: 10.1002/iid3.426. PMID: 33945643
Mice co-injected intravenously with 5 μg of anti-CD3 (clone CL2) and an anti-cytokine cocktail (anti-IL-2, IL-6, IFN-γ, TNF-α, 30 mg/kg each) showed transient improvement in cytokine release syndrome (CRS) features. The model, replicating T-cell activation and extramedullary hematopoiesis, supports evaluation of anti-cytokine strategies for human CRS.
Tags: anti-human CD62E (E-selectin) CL2 in animal model; anti-human CD62E (E-selectin) antibody (clone CL2)
Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model
Prodeus, A., et al. Sci Rep. 2022 Mar 3;12(1):3456. doi: 10.1038/s41598-022-06953-7. PMID: 35241728
A humanized CD3E mouse model evaluated the anti-CD3ε antibody (clone CL2), which activated T cells in vitro and depleted nearly 100% of peripheral B cells in vivo when targeting CD20. The model, showing normal thymic development, supports preclinical testing of T-cell engagers like anti-CD3/CD19 and anti-CD3/BCMA antibodies.
Tags: anti-human CD62E (E-selectin) CL2 in cancer research; anti-human CD62E (E-selectin) antibody CL2
Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy
Mok, S., et al. J Natl Cancer Inst. 2010 Dec 15;102(24):1843-54. doi: 10.1093/jnci/djq419. PMID: 21116835
Intraperitoneal administration of anti-mouse and anti-human CCL2 antibodies (2 mg/kg/dose, twice weekly) with temozolomide prolonged survival in C57BL/6 mice bearing GL261 glioma (8/10 survived >70 days vs. 3/10 with control IgG, P=0.0359). The treatment reduced tumor-associated macrophages and myeloid-derived suppressor cells, enhancing anti-tumor immune responses.
Tags: anti-human CD62E (E-selectin) CL2 in human tumor model; clone CL2 of human CD62E (E-selectin) antibody
For more references about anti-human CD62E (E-selectin) antibody (CL2), please contact our scientific support team with message@sydlabs.com.